Dimetilfumarato. Una alternativa terapéutica en la psoriasis

David Aldo De Luca

doi:10.47196/da.v26i3.2100

Authors

David Aldo De Luca Private practice, Bad Neustadt a.d. Saale, Bavaria, Germany

DOI:

https://doi.org/10.47196/da.v26i3.2100

Keywords:

dimethyl fumarate, fumaric acid esters, psoriasis

Abstract

Fumaric acid esters have been empirically used for decades for the management of moderate to severe psoriasis that requires systemic treatment. Both its immunomodulatory effect and its low rate of serious adverse effects make it attractive as a therapeutic option in patients who do not respond to other treatments or who have certain contraindications to the usual therapies. A bibliographic update on dimethyl fumarate in the treatment of moderate to severe psoriasis is presented, highlighting its mechanism of action, its dosage, its unwanted effects and the studies that support its use in psoriasis.

Author Biography

David Aldo De Luca, Private practice, Bad Neustadt a.d. Saale, Bavaria, Germany

Dermatology Specialist, M.Sc. Molecular Biology

References

I. Martinez Lombardo MA, Cano Ortiz A. Plantas medicinales con alcaloides en la provincia de Jaén. Boletín del Instituto de Estudios Giennenses 2009;200:125-163.

II. Rotering F. Ésteres de ácido fumárico (Fumaderm) en psoriasis. Arznei-Telegramm 2013;44:35-36.

III. Balak DM. Fumaric acid esters in the management of psoriasis. Psoriasis (Auckl) 2015;5:9-23.

IV. Silvestre JF, Mercader P, Giménez-Arnau AM. Dermatitis de contacto por dimetilfumarato. Actas Dermosifiliogr 2010;101:217-222.

V. Skilarence®. Anexo I. Ficha técnica o resumen de las características del producto. [en línea], Agencia Europea de Medicamentos. 23 de junio 2017. Disponible en: <https://ec.europa.eu/health/documents/community-register/2017/20170623138037/anx_138037_es.pdf> [consultado abril 2020].

VI. Brück J, Dringen R, Amasuno A, Pau-Charles I, et ál. A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Exp Dermatol 2018;27:611-624.

VII. Ceglowska U, Wlodarczyk A, Slomka M. Clinical effectiveness of fumaric acid esters (Fumaderm) in psoriasis: A systematic review of literature. Value Health 2014;17:A605.

VIII. Disposición 9666 [en línea], Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, 26 de agosto de 2016. Disponible en: <http://www.anmat.gov.ar/boletin_anmat/agosto_2016/Dispo_9666-16.pdf> [consultado mayo 2020].

IX. Meissner M, Valesky EM, Kippenberger S, Kaufmann R, et ál. Dimethyl fumarate - only an anti-psoriatic medication? J Dtsch Dermatol Ges 2012;10:793-801.

X. Blair HA. Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis. Drugs 2018;78:123-130.

XI. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, et ál. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol 2009;129:231-234.

XII. Ghoreschi K, Brück J, Kellerer C, Deng C, et ál. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011;208:2291-2303.

XIII. Lehmann JC, Listopad JJ, Rentzsch CU, Igney FH, et ál. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007;127:835-845.

XIV. Gillard GO, Collette B, Anderson J, Chao J, et ál. DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner. J Neuroimmunol 2015;283:74-85.

XV. Litjens NH, Rademaker M, Ravensbergen B, Rea D, et ál. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004;34:565-575.

XVI. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an Inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997;234:19-23.

XVII. Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, et ál. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem 2012;287:28017-28026.

XVIII. Zhao G, Liu Y, Fang J, Chen Y, et ál. Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α). Biochem Biophys Res Commun 2014;448:303-307.

XIX. Li Y, Tang J, Hu Y. Dimethyl fumarate protection against collagen II degradation. Biochem Biophys Res Commun 2014;454:257-261.

XX. Schmitz L, Oster-Schmidt C. Ésteres de ácido fumárico. En: Schmitz L, Oster-Schmidt C. Terapéutica sistémica en la dermatología. Stuttgart: Thieme; 2016:195-198.

XXI. Safety Data Sheet - Dimethyl fumarate. [En línea], Thermo Fischer Scientific, Estados Unidos, enero de 2018. Disponible en: <https://www.fishersci.com/> [consultado octubre 2020].

XXII. Balak DM, Bouwes Bavinck JN, De Vries AP, Hartman J, et ál. Drug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case series. Clin Kidney J 2016;9:82-89.

XXIII. Mrowietz U, Barker J, Boehncke WH, Iversen L, et ál. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol 2018;32 Suppl 3:3-14.

XXIV. Reich K, Thaci D, Mrowietz U, Kamps A, et ál. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis-a retrospective study (FUTURE). J Dtsch Dermatol Ges 2009;7:603-611.

XXV. Gieselbach RJ, Muller-Hansma AH, Wijburg MT, De Bruin-Weller MS, et ál. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 2017;264:1155-1164.

XXVI. Everage NJ, Liu S, Yun J, Prada C, et ál. 053 Pregnancy outcomes with delayed-release dimethyl fumarate: interim results from an international registry. J Neurol Neurosurg Psychiatry 2018;89:A22.

XXVII. Mrowietz U, Szepietowski JC, Loewe R, Van de Kerkhof P, et ál. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE). Br J Dermatol 2017;176:615-623.

XXVIII. Inzinger M, Weger W, Heschl B, Salmhofer W, et ál. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. J Eur Acad Dermatol Venereol 2013;27:861-866.

XXIX. Nast A, Amelunxen L, Augustin M, WH Boehncke et ál. S3 - Pautas de tratamiento de la psoriasis vulgar. Actualización parte 1: Terapéutica sistémica. J Dtsch Dermatol Ges 2018;16:645-670.

XXX. Reich K, Hartl C, Gambichler T, Zschocke I. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). J Dtsch Dermatol Ges 2016;14:50-58.